fbpx

molecules of the month

S62798 (Servier)

fibrinolytic TAFIa carboxypeptidase inhibitor

Ph. II candidate for pulm. embolism; discont.

from literature pharmacophore and SBDD

J. Med. Chem., Mar. 25, 2021

Servier, Croissy-sur-Seine, FR

S62798-(Servier)
1 min read

The Servier thrombin activatable fibrinolysis inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot degrading) agent which entered Ph. II in the EU for pulmonary embolism, but development appears to have been cancelled. TAFIa inhibitors are suggested to reduce clotting risk without  the risk of major hemorrhage since they don’t interfere with platelet activation and blood coagulation. The phosphinic acid acts as a zinc binding motif, and was cyclized in order to reduce conformational flexibility and increase selectivity against other carboxypeptidases. This phosphorus-containing molecule has interesting drug properties as it is a highly polar, renally excreted compound possessing two acidic sites and multiple potentially basic atoms. The binding mode is also interesting with numerous highly polar interactions including zinc metal-binding within a short…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: